The antitrust trial involving Gilead and Teva over inflated HIV drug prices is set to begin on Thursday. However, the two drugmakers reached a last-minute agreement with major pharmacies, and Gilead settled with direct purchasers. The remaining claims will be taken to a California federal jury.
U.S. District Judge Edward M. Chen has announced settlements ahead of Thursday’s openings, reported Law360. The settlements resolve claims against Gilead and Teva by retailer plaintiffs such as Walgreens, CVS and Rite Aid, and claims against Gilead by two classes of direct purchaser plaintiffs, which include KPH Healthcare Services Inc.
The plaintiffs have claimed that Gilead and Teva entered into an agreement that hindered the entry of generic drug makers into the market for specific HIV drugs, leading to higher drug costs and a breach of federal antitrust laws.
Read more: Gilead And Teva’s HIV Antitrust Trial Begins
Following the legal confirmation of settlements with a Gilead lawyer, Judge Chen expressed satisfaction with the outcome.
“It seemed to me that it makes imminent sense to resolve this case … given the huge range of potential outcomes,” the judge said, adding that the mediator “has done a masterful job.”
The trial then went forward with the remaining plaintiffs: United Healthcare Services, individual health plan purchasers and indirect purchaser classes.
Featured News
Walmart Withdraws and Refiles Antitrust Review Application for Vizio Acquisition
Mar 28, 2024 by
CPI
Apple Prevails in Dismissal of Crypto-Payment Antitrust Lawsuit
Mar 27, 2024 by
CPI
Amazon Fined in Poland for Misleading Customers
Mar 27, 2024 by
CPI
Credit Card Rewards Under Threat as Visa, Mastercard Settlement Impacts Swipe Fees
Mar 27, 2024 by
CPI
UK Fashion Giants Commit to Honest Environmental Claims
Mar 27, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Real Estate & Antitrust
Mar 27, 2024 by
CPI
Systematic National Evidence of Steering by Real Estate Agents
Mar 27, 2024 by
CPI
Compliance Now! Actionable Antitrust Advice for the Residential Real Estate Industry
Mar 27, 2024 by
CPI
Real Estate Commissions: Some Insights from the Economics of Multi-Sided Platforms
Mar 27, 2024 by
CPI
New Ideas for Promoting Real Estate Brokerage Price Competition
Mar 27, 2024 by
CPI